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Chorea is a movement disorder that may be found in children due to several causes. Here we focus especially
on Systemic Lupus Erythematosus associated chorea. First we outline its epidemiology, hypothesized pathogenesis,
clinical presentation and treatment, then we report four significant clinical cases, which represent well the extreme
variability of set of symptoms that may accompany lupus chorea. Our experience, according to literature, suggests
that choreic movements in a child should alert the pediatrician and lead him to investigate a potential neurological
involvement of Systemic Lupus Erythematosus.Background
The term chorea (choreia = dance) defines a movement
disorder and a syndrome characterized by not repetitive
sudden involuntary movements, that may involve any
portion of the body.
Chorea may occur in the context of various diseases
(Table 1). Even if the most common etiology of chorea
in pediatric patients is the autoimmune form of post-
streptococcal origin [1], chorea may be also a complication
of Systemic Lupus Erythematosus (SLE).
SLE is a systemic autoimmune disease characterized by
the presence of autoantibodies and multiorgan involve-
ment. Clinical presentation of the disease is extremely
variable. The classification of SLE is established on the
basis of specific criteria [3], which include only psychosis
and seizures as nervous system manifestations; neverthe-
less also other neuropsychiatric disorders are associated
with SLE (neuropsychiatric SLE). Neuropsychiatric SLE
is reported in 20% to 95% patients with pediatric SLE
[4]. In 1999 the American College of Rheumatology
(ACR) compiled a standardized nomenclature, providing
case definitions for 19 neuropsychiatric syndromes seen
in SLE as described in Table 2 [5].* Correspondence: torreggiani.sofia@hotmail.it
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chorea plays a leading role, being the most frequent
one (0-5% of all patients with pediatric SLE) [4].
The pathogenesis of lupus-associated chorea is still
unclear, but it may be related to a vascular, neuronal and
glial injury. Vascular damage may be inflammatory and/
or thrombotic. Ischemic pathology is often due to auto-
antibodies, mainly antiphospholipid antibodies (aPL).
Antiphospholipid antibodies seem to play a decisive role
in neuropsychiatric SLE pathogenesis. Positive finding
of aPL can be based on an abnormal serum level of IgG
or IgM anticardiolipin antibodies (aCL), on an abnormal
serum level of IgG or IgM anti-beta 2 glycoprotein I anti-
bodies or on a positive test result for lupus anticoagulant
(LAC) using a standard method. The prevalence of anti-
beta 2 glycoprotein I antibodies is higher in SLE patients
with neuropsychiatric disease compared with those with-
out. Antiphospholipid antibodies are more frequently
identified in patient with lupus chorea, than in all patients
with SLE [6]. It was demonstrated an association between
a persistently positive LAC and chorea [7].
In some studies it was emphasized the direct role of
aPL and anti-beta 2 glycoprotein I antibodies, which would
act not only through their procoagulant effects, but also
causing direct damage to neuronal cells. It was shown that
IgG isolated from the serum of patients with aPL at high
titer are able to depolarize synaptoneurosomes purified
from cerebral cortex of rats: this was the first evidence oftral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Differential diagnosis of chorea in pediatric age
Etiology Specific conditions
Central nervous system infections Herpes simplex virus, varicella zoster virus, paramyxovirus (measles), HIV, lyme disease, mycoplasma
Autoimmune Sydenham chorea, systemic lupus erythematosus, antiphospholipid syndrome,
Neuro-Behcet, primary central nervous system vasculitis
Neurodegenerative, metabolic, genetic Huntington’s disease, Phenylketonuria, Wilson disease, mitochondrial pathologies
Vascular Stroke, post-cardiac transplant, arteriovenous malformation, moya-moya disease
Endocrinological Hyperthyroidism
Toxic Anticholinergic toxicity, dopamine antagonists, carbon monoxide, neuroleptic drugs.
Modified from Luca NJ et al. Paediatr Child Health 2011 [2].
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manifestations in the absence of documentable thrombo-
embolic damage in the CNS and other abnormalities at
MRI [8].
In the pathogenesis of diffuse neuropsychiatric symp-
toms, also antineuronal antibodies, antibodies against
ribosomal P-protein and cytokines have been documented
to play a role [9].
Some data suggest that also sex hormones may be
involved in the pathogenesis of chorea, especially after
case reports of SLE chorea during pregnancy (Chorea
Gravidarum) [10].
Chorea can appear at any time during pediatric SLE,
during both the active disease and the clinical remission.
It can represent the first clinical manifestation of SLE [11],
preceding the other signs that are among the classification
criteria [12]; alternatively, it can appear at a later time,
even after several months from the onset of the disease.
Chorea typically manifests with jerky, involuntary and
purposeless movements, mainly involving the four limbs.
Patients with chorea may have difficulty walking andTable 2 Neuropsychiatric syndromes observed in SLE
Central nervous system Peripheral nervous system
● Aseptic meningitis ● Acute inflammatory demyelinating
polyradiculoneuropathy
(Guillain-Barré syndrome)● Cerebrovascular disease
● Demyelinating syndrome




● Movement disorder (chorea) ● Mononeuropathy, single/multiplex
● Myelopathy ● Myasthenia gravis
● Seizure disorders ● Neuropathy, cranial
● Acute confusional state ● Plexopathy




The American College of Rheumatology nomenclature and case definitions for
neuropsychiatric lupus syndromes. Arthritis Rheum 1999, 42(4):599–608.keeping the upright posture; loss of coordination of
tongue and hands muscles can cause dysarthria and
difficulties in writing. All symptoms are accentuated
by stress or excitement, while they are reduced during
rest and sleep.
Difficulties in the diagnosis of neuropsychiatric SLE lie
mainly in the fact that clinical symptoms, often relevant,
may occur without any detectable lesion at neuroimaging
[13]; conversely anatomical and/or functional alterations
are described in patients without symptoms or signs of
neuropsychiatric pathology [14]. Magnetic resonance
imaging (MRI) is more sensitive than computed tomog-
raphy (CT) for neuropsychiatric SLE-associated lesions,
even if neuroimaging findings don’t always relate spe-
cifically with the clinical picture. Electroencephalo-
graphic (EEG) evaluation presents the same problem.
Positron emission tomography (PET) scan using [18 F]
deoxy-glucose has shown hypermetabolism in the contra-
lateral striatum in patients with SLE chorea compared
with normal controls [15]. Similar findings were also
observed in other forms of suspected autoimmune chorea
[16], in contrast to the striatal hypometabolism observed
in vascular and hereditary neurodegenerative chorea [17].
Quantitative imaging techniques such as volumetric
magnetisation transfer imaging (MTI) are able to show
diffuse tissue abnormalities not visible on normal MR
analysis. MTI histogram peak height values in neuro-
psychiatric SLE were lower than in controls or patients
with SLE without neuropsychiatric symptoms. Moreover,
MTI parameters in the active phase of neuropsychiatric
SLE are different from those in the chronic phase [18].
The inadequate knowledge of pathogenetic mechanisms
and the lack of randomized-controlled trials imply that
the treatment of chorea in SLE is not yet completely
codified. The most recent EULAR recommendations
for the management of SLE with neuropsychiatric
manifestations advise to treat patients with persistent
choreic symptoms with dopamine antagonists; it is also
recommended to consider antiplatelet therapy in aPL
positive patients. Anticoagulation should be reserved
for patients with positive aPL who experienced a clinical
thromboembolic event [19]. Glucocorticoids in combination
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phosphamide) may be used to control NPSLE disease
activity [20].
Case presentation
83 patients diagnosed with SLE (13 males and 70 females)
are followed at our division of Pediatric Rheumatology.
At the onset of SLE symptoms, their average age was of
11,3 +/− 2,7 years (range 1–16 years). 43 patients had
neuropsychiatric involvement; among them 5 presented
chorea (11,6% of the patients with neuropsychiatric
SLE and 6% of the patients with SLE). In our clinical
records, in agreement with the literature, we have found a
correlation between chorea and aPL positivity. Patients
with chorea showed a more severe disease and a worse
prognosis.
Case 1: chorea, arthritis, SLE
A 12-year old previously healthy girl was admitted to
our division due to ataxic gait and choreic movements.
She also complained of asthenia, difficulty concentrating,
depression and decline in school performance. Blood
tests performed after admission showed: positive ANA
(1:2560), aCL, anti-DNA antibodies and Coombs test; LAC
was negative. The EEG documented a modest alteration
of the overall organization, expressed in a symmetrical
manner in the two hemispheres, and independent focal
slow-wave abnormalities in the left temporal and right
occipital, where sporadic epileptiform abnormalities
were also found. MRI documented nonspecific punctate
hyperintensities bilaterally at the level of the medial
fronto-parietal subcortical white matter. During hospi-
talization, the patient developed arthritis that involved
all the fingers of the hands, wrists and knees; choreic
movements of the upper limbs were also present. SLE
diagnosis was confirmed by the presence of the classifi-
cation criteria and supported also by the neurological
involvement (chorea). Intravenous therapy with steroids
(methylprednisolone acetate, 20 mg/ kg/day administred
for 3 consecutive days) led quickly to the complete remis-
sion of the choreic symptoms. Treatment was prosecuted
with oral prednisone (1 mg/kg/day), with gradual tapering
thereafter. During the subsequent 5 years of follow-up, the
patient no longer experienced movement disorders. On
the other hand, at the age of 13, she presented a major
renal involvement (proliferative glomerulonephritis, Class
III), hypertension, deep vein thrombosis.Case 2: epilepsy, coma, vascular malformation, chorea, SLE
The girl, carrier of glucose-6-phosphate dehydrogenase
deficiency, enjoyed good health until the age of 3, when
she had seizures characterized by loss of consciousness
with hypotonia. She was diagnosed with idiopathic partialepilepsy and was treated first with carbamazepine and
then with valproic acid, with no more evidence of seizures,
so that antiepileptic therapy was suspended.
At the age of 6, she had an important episode of head-
ache with vomiting and backache, followed by a progressive
state of coma. She was admitted to the local hospital. Brain
CT scan documented a massive left frontal intraparen-
chymal hematoma with endoventricular haemorrhage.
The girl started therapy with steroids and tranexamic
acid, with marked improvement of the clinical picture.
Subsequently, CT and MRI described resorption of the
hematoma, but showed in the same location a porence-
phalic cavity communicating with the frontal horn of the
lateral ventricle. Angiography documented the presence of
an arteriovenous vascular malformation, subsequently
removed by surgery. The exams showed positive LAC,
increased APTT and reduction of coagulation factors
VIII and IX.
At the age of 11, the girl presented hand swellings.
Blood tests showed positive ANA (1:160), positive anti-
DNA antibodies, low C4 (3 mg/dL). Capillaroscopy doc-
umented nonspecific microangiopathic alterations with
features of acrocyanosis. Due to suspected SLE, she was
treated with steroid (deflazacort 1,2 mg/kg/day) and
acetylsalicylic acid (ASA, 100 mg/day).
She experienced clinical well-being until the age of 12,
when, after reduction of steroid therapy (deflazacort
0,3 mg/kg/day), swellings reappeared, involving wrists,
fingers and elbows. Methotrexate therapy was started
(10 mg/m2 once a week), with benefit; it was suspended
one year later due to an increase in liver enzymes. In
that occasion, at the age of 13, the girl repeated blood
tests which showed: positive aCL, LAC and IgM anti-beta
2 glycoprotein I, erythrocyte sedimentation rate (ESR)
22 mm/hr, C3 44 mg/dL, C4 2 mg/dL, positive ANA
(1:320), positive anti-DNA antibodies, thrombocytopenia
(67000/mm3). Considering SLE diagnosis, azathioprine
(2,12 mg/kg/day) was added to the steroid therapy
(prednisone 0,5 mg/kg/day). Due to glucose-6-phosphate
dehydrogenase deficiency, treatment with hydroxy-
chloroquine was not prescribed. Two months later, the
patient showed hyperkinesis in the right hemibody and
especially in the tongue, with subsequent dysarthria. In
the following weeks, she developed generalized chorea,
mainly in the right hemibody. The MRI didn’t show
changes from the previous ones. At the same time
butterfly rash appeared. The girl was transferred to our
division, where diagnosis of SLE was confirmed, since
during the clinical history of the patient the classification
criteria were present. Chorea was attributable to neu-
ropsychiatric lupus. Choreic symptoms regressed after
administration of intravenous methylprednisolone acetate
(20 mg/ kg/day for 3 consecutive days), therapy was prose-
cuted with oral prednisone (0,75 mg/kg/day). Azathioprine
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suspended.
At the age of 14 years, following the tapering of cor-
ticosteroid therapy, choreic movements reappeared. As
in the whole clinical history, also in this occasion blood
tests showed positive LAC. The MRI didn’t reveal recent
parenchymal lesions (Figure 1). Treatment with intravenous
methylprednisolone acetate (20 mg/kg/day, administered
for 3 consecutive days) rapidly improved the symptoms;
therapy was prosecuted with oral prednisone (0,75 mg/kg/
day). In the 10 months of follow-up the girl didn’t show
other choreic movements.
Case 3: fever, myalgias, aphtae, opisthotonus, chorea,
diffuse proliferative glomerulonephritis, SLE
The patient was in good health until the age of 14, when
she presented hyperpyrexia, diffuse myalgias, oral aphtae,
an episode of marked agitation, opisthotonus and diffuse
hyperalgia.
She underwent an EEG, which showed widespread
brain injury; brain CT scan documented in the left hemi-
sphere a faint subcortical fronto-temporal hypodensity,
with blurred limits. Antibiotic, antiviral and anti-edema
therapy was started, but 3 days after admission, choreic
movements and incomprehensible speech appeared. Blood
tests showed increased inflammatory markers (ESR
110 mm/hr, C-Reactive Protein 50 mg/dL - normal
values <1 mg/dL), hypocomplementemia, positive ANA
and anti-DNA, negative LAC, microscopic hematuria
and proteinuria; aCL were not investigated, since at
that time it was not yet a routine test. One week after
the onset of symptoms, the patient was transferred to our
division: she still had choreic movements of the four
limbs; her gait was ataxic and she was not able to walkFigure 1 Brain MRI of case 2. T2-weighted images on brain MRI showing
left frontal craniotomy) and a malacic area, communicating with the omolawith eyes closed. The presence of oral ulcers, pathological
proteinuria, positive ANA and anti-DNA allowed a diag-
nosis of SLE. She started steroid therapy with intravenous
methylprednisolone acetate (20 mg/ kg/day), administered
for 3 consecutive days, prosecuted with oral prednisone
(1 mg/kg/day). In the following days, choreic symptoms
worsened: brain MRI showed punctate subcortical hyper-
intensities in both cerebral hemispheres, suggestive of a
vasculitic process. Failure of steroid therapy, neurological
symptoms and important renal involvement (diffuse
proliferative glomerulonephritis, Class IV) justified the
use of intravenous cyclophosphamide (0,5 mg/m2 of body
surface area, once a month for 6 months and then once
every two months for other 6 months). 15 days after
the first cyclophsphamide pulse, the choreic symptoms
resolved, also with the use of haloperidol. In the last
8 years of follow-up, being the girl treated with low-dose
steroid therapy, values of proteinuria normalized and the
patient no longer showed choreic symptoms or other
neurologic manifestations.
Case 4: SLE, chorea, diffuse proliferative
glomerulonephritis
The child enjoyed good health until he was 10, when he
started presenting asthenia, arthralgias and abdominal
pain. He was admitted to another hospital, where blood
tests showed microscopic hematuria, hypocomplementemia
(C3 11 mg/dL and C4 3 mg/dL), positivity for ANA
(1:2560), anti-DNA and LAC. In suspected SLE, the child
was sent to our division, where he showed the butterfly
rash and arthritis involving both wrists, all proximal
interphalangeal joints and metacarpophalangeal joints
of the second and third finger of both hands. In view of
the clinical examination, the renal involvement, the, in the left supratentorial region, the known surgical outcomes (with
teral frontal horn. No further significant signal alterations are evident.
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was confirmed, also supported by hypocomplementemia
and pathological capillaroscopic findings. Intravenous
methylprednisolone acetate (20 mg/kg/day) was adminis-
tered for 3 consecutive days, followed by oral prednisone
(1 mg/kg/day, with gradual tapering thereafter).
Seven months after the onset of the disease, when
prednisone was at the dose of 0,65 mg/kg/day, choreic
movements of the four limbs appeared; butterfly rash
and oral apthae were also present. He was therefore
hospitalized a second time; brain MRI showed multiple
lesions of vasculitic origin in both hemispheres, while EEG
results were normal. After the detection of proteinuria
(1,6-2 g/24 h), renal biopsy was performed and docu-
mented diffuse proliferative glomerulonephritis, Class IV.
Blood tests showed positive LAC and aCL and severe
thrombocytopenia (3000/mm3), which required a plate-
let transfusion. Intravenous methylprednisolone acetate
(20 mg/ kg/day) was administered for 3 consecutive days;
tiapride hydrochloride was used as a symptomatic therapy;
oral treatment with prednisone (1 mg/kg/day) followed.
Due to persistent thrombocytopenia, intravenous immuno-
globulin was administered for 5 consecutive days, with
progressive increase in the number of platelets. Severe
disease activity and renal involvement justified the use
of cyclophosphamide (0,5 mg/m2 of body surface area,
once a month for 6 months and then once every
2 months for other 10 months).
At the age of 13 years, only one week after the last
cyclophosphamide pulse and following a reduction of
steroid therapy (0,25 mg/Kg/day), left hemichorea
appeared. The boy was admitted to our division; the
MRI didn’t show changes from the previous one;
LAC was positive (aCL were not measured). Due to
mild neurologic symptoms, treatment with tiapride
hydrochloride was not considered necessary. Intravenous
methylprednisolone acetate (20 mg/ kg/day) was ad-
ministered for 3 consecutive days, with improvement of
the symptoms; tapered oral therapy with prednisone
followed. During 9 years of follow-up after the last choreicTable 3 Clinical features and outcomes of SLE associated cho
Case 1 2
Onset of chorea 12 years 13 years
At the onset of SLE 2 years after SLE onset
Positive LAC and/or aCL Yes Yes
Neuroimaging Not specific lesions Picture mainly characterized b




Recurrence of chorea No 1 year after the first episode
Renal involvement Class III Nomanifestations, the boy didn’t experience other neurologic
symptoms, but at the age of 18 worsening of the renal
disease (switch from Class IV to Classes II and V), required
treatment with mycophenolate mofetil.
Discussion
Neuropsychiatric SLE was found in 51,8% of our SLE
patients; this prevalence is included in the wide range
reported in literature (20-95%). On the contrary, prevalence
of chorea was slightly higher: we recorded it in 6% of our
SLE patients (instead of 0-5% [4]).
Clinical features of SLE associated chorea in our patients
are summarized in Table 3.
In our clinical records, chorea occurred at different
times during SLE disease. In according to literature, in 3
cases it appeared relatively early [11,12]: chorea was
present at the onset of SLE in two cases (1 and 3) and it
appeared 7 months after SLE diagnosis in case 4. Only
in case 2 chorea appeared 2 years after SLE onset. Age
at the onset of chorea ranged between 11 and 14 years.
When investigated, LAC and/or aCL were positive
(case 1,2, and 4); in case 3 LAC was negative, while, due
to the techniques available at that time, aCL were not
measured at chorea onset, before starting therapy with
steroid and cyclophosphamide.
Neuroimaging showed vasculitic findings in case 3 and
4; in case 1 the lesions detected were not specific. In
case 2 the picture was mainly characterized by the
porencephalic cavity and the previous surgery; as in a
previous case report, in which the child had experienced
a cerebral infarction before developing involuntary
movements [21], MRI performed at the onset of chorea
revealed no new lesions.
The multiorgan involvement associated with chorea in
our patients justified steroid treatment. High-dose steroid
therapy was able to reduce choreic manifestations, except
in case 3 in which cyclophsphamide seemed to improve
the neurological picture. In order to control choreic symp-
toms, haloperidol and tiapride hydrochloride were also
used in association with the steroid therapy, with benefit.rea in our patients
3 4
14 years 11 years




Vasculitic findings Vasculitic findings
No Yes
No 2 years after the first episode
Class IV Class IV and later
Classes II and V
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case 2 after one year, in case 4 after 2 years), following a
decrease of oral steroid therapy. In case 4, cyclophospha-
mide administered for the renal involvement did not
prevent the recurrence of chorea, which appeared only
one week after the last pulse; nevertheless, symptoms
were milder compared to the first episode, therefore
cyclophosphamide may have played a role in reducing
the severity of neurologic manifestations.
All patients with chorea showed a severe SLE disease:
3 of them had renal involvement (1, 3 e 4), with different
histopathological patterns (Classes II, III, IV and V).
Renal disease was associated with chorea also in another
case reported in the literature, even if in that patient
lupus nephritis occurred before chorea [21].
Chronic and end-stage renal disease is known to be a
significant cause of morbidity and mortality in SLE
patients [22]; this is true also in childhood-onset SLE,
where incidence of nephritis can be higher than in
adult-onset disease [23]. Advanced renal scarring with
significant loss of functional nephrons is not reversible,
even with immunosuppressive therapy, and leads to severe
consequences. The fact that chorea appears early in the
disease, makes its recognition as a SLE manifestation even
more important. If SLE is diagnosed, a proper therapy can
be started and, even if kidney disease cannot be prevented,
more severe renal complications could be avoided, improv-
ing dramatically the prognosis of the patient.
Conclusions
It’s important to remember the association between
chorea and SLE. If a patient shows choreic movements,
after excluding the most frequent etiologies, it should
be considered that chorea may represent the neurologic
involvement of SLE. The most common pediatric chorea
is Sydenham chorea, but it should be considered that
its incidence is expected to decrease, due to the reduced
incidence of rheumatic fever in the Western countries
[24]; in Latin America, Africa, and parts of Asia, the
frequency of rheumatic fever and Sydenham chorea is
higher, but it shows a trend towards reduction also in
these regions [25]. Lupus associated chorea, even if less
frequent, deserves a special attention for its clinical
relevance: if Sydenham chorea is unrecognized, the
prognosis quoad vitam is not significantly affected,
while SLE chorea is related to severe SLE disease, for
which an appropriate treatment is essential.
Currently, the ACR classification criteria for SLE include
only psychosis and seizures as nervous system manifes-
tations, but there are valid reasons for adding to these
neurological disorders also chorea: the frequency of
chorea in pediatric SLE is significant; furthermore,
lupus chorea usually appears early in the disease, therefore
recognizing it among the criteria could be an opportunityto anticipate SLE diagnosis and offer the patients a timely
therapy, potentially able to reduce systemic complications
of SLE.
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